Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HMGCR | P04035 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984249 | 0.93 | RECQL (0.55) | PTPN7RECQLTDP1KDM4EMEN1 | |
| SCHEMBL1551102 | 0.93 | PTPN7 (0.46) | PTPN7RECQLTDP1KDM4EMEN1 | |
| SCHEMBL10900975 | 0.91 | PTPN7 (0.53) | PTPN7RECQLTDP1KDM4EMEN1 | |
| SCHEMBL3862473 | 0.90 | PTPN7 (0.50) | PTPN7RECQLTDP1KDM4EMEN1 | |
| SCHEMBL3215602 | 0.90 | PTPN7 (0.50) | PTPN7RECQLTDP1KDM4EMEN1 | |
| SCHEMBL7992241 | 0.90 | PTPN7 (0.50) | PTPN7RECQLTDP1KDM4EMEN1 | |
| SCHEMBL3857559 | 0.90 | PTPN7 (0.50) | PTPN7RECQLTDP1KDM4EMEN1 | |
| SCHEMBL9344342 | 0.90 | PTPN7 (0.50) | PTPN7RECQLTDP1KDM4EMEN1 | |
| SCHEMBL17608683 | 0.90 | PTPN7 (0.50) | PTPN7RECQLTDP1KDM4EMEN1 | |
| SCHEMBL3861223 | 0.87 | PTPN7 (0.46) | PTPN7RECQLTDP1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390378-B1 | PHARMACEUTICALLY ACTIVE URIDINE ESTERS | TROMMSDORFF ARZNEIMITTEL (DE) | 2009-06-17 | — | — | EP | claimed |
| US-7396826-B2 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2008-07-08 | — | — | US | claimed |
| US-20040121979-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2004-06-24 | — | — | US | claimed |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-17 | — | — | US | disclosed |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-08-27 | — | — | US | disclosed |
| EP-2827899-B1 | POLYSACCHARIDE ANTIGEN-GLYCOLIPID CONJUGATE VACCINES | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-7915234-B2 | Synergistic mixture; antioxidant; cardiovascular disorders; antidiabetic agents | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2011-03-29 | — | — | US | disclosed |
| US-7560442-B2 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2009-07-14 | — | — | US | disclosed |
| EP-1390378-B1 | PHARMACEUTICALLY ACTIVE URIDINE ESTERS | TROMMSDORFF ARZNEIMITTEL (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-7417034-B2 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZENEIMITTEL (DE) | 2008-08-26 | — | — | US | disclosed |
| US-7396826-B2 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2008-07-08 | — | — | US | disclosed |
| EP-1666092-A2 | Drug combination comprising a fatty acid and a uridine compound. | Trommsdorff GmbH & Co.KG Arzneimittel (DE) | 2006-06-07 | — | — | EP | disclosed |
| US-20050065110-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO., KG ARZNEIMITTEL | 2005-03-24 | — | — | US | disclosed |
| US-20050043269-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL | 2005-02-24 | — | — | US | disclosed |
| US-20050043394-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL | 2005-02-24 | — | — | US | disclosed |
| US-20040121979-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043394-A1 | Pharmaceutically active uridine esters | UMPS, UGDH, FFAR3 | PTPN7 4387/4885RECQL 587/4885TDP1 1664/4885 |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | STT3B, STT3A, DDOST | PTPN7 1933/4885RECQL 2785/4885TDP1 4777/4885 |
| US-20040121979-A1 | Pharmaceutically active uridine esters | UMPS, UGDH, FFAR1 | PTPN7 4353/4885RECQL 739/4885TDP1 1177/4885 |
| US-20050043269-A1 | Pharmaceutically active uridine esters | UMPS, UGDH, FFAR3 | PTPN7 4387/4885RECQL 587/4885TDP1 1664/4885 |
| US-20050065110-A1 | Pharmaceutically active uridine esters | UMPS, UGDH, FFAR3 | PTPN7 4387/4885RECQL 587/4885TDP1 1664/4885 |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | STT3B, STT3A, DDOST | PTPN7 1933/4885RECQL 2785/4885TDP1 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.